scholarly journals Downbeat nystagmus and other characteristic ENG findings in a patient with bipolar disorder receiving lithium carbonate

2021 ◽  
Vol 80 (1) ◽  
pp. 10-23
Author(s):  
Jun-Ichi Yokota ◽  
Ayako Inoshita ◽  
Masamori Sato ◽  
Yoko Yamaguchi
2016 ◽  
Vol 10 (1) ◽  
pp. 126-128 ◽  
Author(s):  
Jesper Skovlund Jørgensen ◽  
Lisbeth Landschoff Lassen ◽  
Marianne Wegener

We report a case of lithium-induced downbeat nystagmus and horizontal gaze palsy in a 62-year-old woman who was treated for a bipolar affective disorder with lithium carbonate for one month. At presentation serum lithium was within therapeutic range. No alternative causes of the ocular motility disturbances were found, and the patient improved significantly as lithium carbonate was discontinued.


2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1
Author(s):  
E. Oral ◽  
E. Ozan ◽  
E. Deveci ◽  
N. Aydın ◽  
I. Kirpinar

Previous studies have suggested that OCD has comorbidity with bipolar disorder (BD) (1,2). We evaluated the three bipolar OCD cases.C1: Because of the OCD symptoms Chlomipramine was started. Her OCD symptoms improved in several days but manic symptoms was apeeared, switched to Lithium Carbonate. In her out patient exams, manic and obsessive compulsive symptoms were almost never observed simultaneously at the course.C2: In 2003, her complaints started as combined OCD and Manic symptoms, Risperidon and Lithium carbonate were started, manic and OCD symptoms improved. In 2005, OCD and Depressive symptoms appeared together. She got improved with Lithium Carbonate and Chlomipramine. She had one episode with obsessive and manic symptoms or obsessive and depressive symptoms every year till now. Her uncle had Depression and her aunt had Bipolar disorder.C3: Because of his OCD symptoms we prescribed SSRI and lower dose antipsychotic. At that time he hospitalized for his manic symptoms, his OCD was partially remitted. His manic symptoms improved with Lithium carbonate1200p/d. He had resistant obsessive compulsive symptoms and episodic manic symptoms. His father had M. Depressive episodes.Conclusion:Our cases suggest that bipolar OCD has episodic course, treatment resistant symtomatology, high family loading and high frequency of recurrence.


Biomédica ◽  
2016 ◽  
Vol 37 ◽  
Author(s):  
Manuel Enrique Machado-Duque ◽  
Catalina Alzate-Carvajal ◽  
Kevin David Zapata ◽  
Jorge Enrique Machado-Alba

Introducción. El litio es el medicamento de elección para el tratamiento del trastorno afectivo bipolar (TAB).Objetivo. Determinar el perfil de uso y reacciones adversas del litio, en pacientes con TAB en Colombia.Materiales y métodos. Estudio observacional de cohorte retrospectiva entre 1 enero y 31 diciembre 2013, se incluyeron pacientes con diagnóstico de TAB tratados con carbonato de litio en 25 ciudades colombianas, evaluando variables socio-demográficas, dosis del litio, comedicación, interacciones medicamentosas y reacciones adversas. Se hizo un análisis multivariado mediante.Resultados. Se hallaron 331 pacientes con edad promedio de 44,5±13,9 años, 59,2% fueron mujeres, la dosis promedio de litio: 898 ± 294 mg/día, el 22% tenían dosis inferiores a recomendadas; en promedio lo han recibido 38,0±39,5 meses (rango: 12-159 meses); solo al 13,5% les realizaron litemia. El 71,3% recibían terapia coadyuvante para TAB con otros medicamentos, especialmente clozapina (16,6%) y ácido valproico (16,6%). Las principales comorbilidades fueron hipotiroidismo (18,1%) e hipertensión arterial (12,7%). Se encontraron 390 interacciones medicamentosas potencialmente toxicas; se reportaron reacciones adversas en 1,2% de casos. Se halló asociación estadísticamente significativa con menor riesgo de recibir terapia combinada al ser tratado en las ciudades de Bogotá (OR:0,4, p=0,025), Cartagena (OR:0,3, p=0,015) e Ibagué (OR:0,3, p=0,025).Conclusiones. El litio se está utilizando en general a dosis e intervalos recomendados, pero un porcentaje significativo recibe dosis inferiores a las recomendadas y no fue posible contrastar el efecto con sus mediciones séricas. Se debe mejorar el reporte de reacciones adversas y medición de litemias en los pacientes con TAB en Colombia.


2021 ◽  
Vol 7 (1) ◽  
pp. 7628-7633
Author(s):  
Caio Silva de Queiroz ◽  
Victória Oliveirade Jesus ◽  
Rafaela Maianna Cruz de Castro Freitas ◽  
Karine Svetlana Sales Carrilho ◽  
Rayssa Gabrielle Pereira de Castro Bueno ◽  
...  

1997 ◽  
Vol 42 (3) ◽  
pp. 298-302 ◽  
Author(s):  
Verinder Sharma ◽  
Dwight S Mazmanian ◽  
Emmanuel Persad ◽  
Karen M Kueneman

Objective This study was conducted to examine how Canadian psychiatrists manage bipolar depression. Method A questionnaire specific to the treatment of bipolar depression was mailed to 1639 active members of the Canadian Psychiatric Association. Results Seven hundred and sixty-six completed questionnaires were returned (46.7%). Most psychiatrists indicated that a combination of psychotherapy and somatic therapy was their preferred approach. For bipolar disorder, depressed, lithium carbonate and selective serotonin reuptake inhibitors (SSRIs) were the preferred treatment strategies. For substitution, tricyclic antidepressants (TCAs) were the favoured choice. Lithium carbonate was the preferred choice for augmentation and addition. Conclusion These findings indicate that a combination of psychotherapy and somatic therapy is the preferred treatment approach for bipolar depression. Lithium carbonate and SSRIs are the favoured somatic therapies.


2020 ◽  
Vol 21 (14) ◽  
pp. 1011-1020
Author(s):  
Sara Sadat Aghabozorg Afjeh ◽  
Jamal Shams ◽  
Safar Hamednia ◽  
Behzad Boshehri ◽  
Amir Olfat ◽  
...  

High rates of mortality due to both suicide and medical comorbidities in bipolar patients can be decreased through the administration of lithium, which affects the cerebral endothelium as well as neurons. To investigate the role of ADCY2 in risk of bipolar disorder, we genotyped the ADCY2 rs2290910 in bipolar patients and healthy controls using amplification refractory mutation system PCR. This polymorphism was associated with risk of bipolar disorder (odds ratio [OR]: 0.430; 95% CI: 0.296–0.624; p = 0.001). The C allele was more frequent in suicide ideation group compared other groups (OR: 2.7; 95% CI: 1.386–5.302; p = 0.004). The T allele was more frequent in suicide attempt group compared with suicide ideation group (OR: 0.238; 95% CI: 0.111–0.509; p = 0.001).


2000 ◽  
Vol 12 (3) ◽  
pp. 136-138 ◽  
Author(s):  
R.L. Findling ◽  
B.L. Gracious ◽  
N.K. McNamara ◽  
J.R. Calabrese

ABSTRACTIntroduction: There are no definitively established acute or maintenance treatments for juvenile bipolar disorder.Method: Two randomized, blind, maintenance clinical trials in children and adolescents with bipolar disorders are ongoing at the University Hospitals of Cleveland/Case Western Reserve University Stanley Clinical Research Center for bipolar disorder. The first is comparing the safety and effectiveness of lithium carbonate (Li+) to divalproex sodium (VPA) for up to 76 weeks in youths with stabilized bipolar illness (type 1 or 2). The second study is designed to compare the efficacy of VPA to placebo in the acute management of subsyndromal symptoms of bipolar disorder (‘cyclotaxia’) and the prevention of the full syndrome in children at risk. Both studies use the prospective life-chart method as an outcome measure.Results: Sixty-six youths have received study medication as part of the trial that is comparing Li+ to VPA as a maintenance therapy. In addition, 32 youths have received blinded treatment as part of the ‘cyclotaxia’ prevention study. Combination Li+A/PA treatment appears generally well tolerated and seems to have robust anti-manic and antidepressant effects.Discussion: Since the blind has not been broken on either of these clinical trials, conclusions about the maintenance effectiveness of either VPA or Li+ in youths with bipolar disorder type 1 or 2 cannot be made yet. Similarly, it is unclear whether VPA is superior to placebo in genetically high-risk youths with cyclotaxia. The final results of these trials should provide valuable information about the treatment of juvenile bipolar disorders.


2020 ◽  
Vol 5 (6) ◽  

Lithium carbonate has been used for over half a century in the management of many psychiatric conditions like persistent depression, self-mutilation behaviors and bipolar disorder, where it has been proven to have benefit in suicide prevention [1]. Nevertheless, many side effects have been linked to its use, some of which include chronic tubule-interstitial disease, nephrogenic diabetes insipidus, thyroid dysfunction and, the focus of this case report, hypercalcemia and hyperparathyroidism [2].


Sign in / Sign up

Export Citation Format

Share Document